{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:31:48Z","timestamp":1787671908654,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00210-026-05525-0","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:03:42Z","timestamp":1780391022000},"page":"17883-17897","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bioequivalence study of Prontogest 100 mg\/2 mL solution for intramuscular injection versus reference progesterone injection, USP 500 mg\/10 mL under fasting conditions: a randomized, open-label, two-sequence, four-period, fully replicated crossover study in healthy postmenopausal women"],"prefix":"10.1007","volume":"399","author":[{"given":"Yasser H.","family":"Habib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Salah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Galal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Gouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youmna","family":"Mosaad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mourad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noran","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mosaad","family":"Morsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"5525_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2025.116960","volume":"264","author":"GP Agrawal","year":"2025","unstructured":"Agrawal GP, Soni K, Alam P, Basu S, Arshad MF (2025) Surrogate matrix approach to quantify endogenous progesterone in a fasting bioequivalence study of soft gelatin capsules in postmenopausal women. J Pharm Biomed Anal 264:116960. https:\/\/doi.org\/10.1016\/j.jpba.2025.116960","journal-title":"J Pharm Biomed Anal"},{"key":"5525_CR2","volume-title":"Design and analysis of bioavailability and bioequivalence studies","author":"SC Chow","year":"1999","unstructured":"Chow SC, Liu J (1999) Design and analysis of bioavailability and bioequivalence studies. CRC Press"},{"issue":"4","key":"5525_CR3","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/wics.1310","volume":"6","author":"S-C Chow","year":"2014","unstructured":"Chow S-C (2014) Bioavailability and bioequivalence in drug development. Wires Comput Stat 6(4):304\u2013312. https:\/\/doi.org\/10.1002\/wics.1310","journal-title":"Wires Comput Stat"},{"issue":"4","key":"5525_CR4","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1208\/s12248-012-9406-x","volume":"14","author":"BM Davit","year":"2012","unstructured":"Davit BM, Chen M-L, Conner DP, Haidar SH, Kim S, Lee CH, Lionberger RA, Makhlouf FT, Nwakama PE, Patel DT, Schuirmann DJ, Yu LX (2012) Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the U.S. Food and Drug Administration. AAPS J 14(4):915\u2013924. https:\/\/doi.org\/10.1208\/s12248-012-9406-x","journal-title":"AAPS J"},{"key":"5525_CR5","unstructured":"European Medicines Agency (2010) Guideline on the investigation of bioequivalence (CPMP\/EWP\/QWP\/1401\/98 Rev. 1\/Corr). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed 26 Feb 2026"},{"issue":"5","key":"5525_CR6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jsps.2013.05.001","volume":"22","author":"UC Galgatte","year":"2014","unstructured":"Galgatte UC, Jamdade VR, Aute PP, Chaudhari PD (2014) Study on requirements of bioequivalence for registration of pharmaceutical products in USA, Europe and Canada. Saudi Pharm J 22(5):391\u2013402. https:\/\/doi.org\/10.1016\/j.jsps.2013.05.001","journal-title":"Saudi Pharm J"},{"issue":"3","key":"5525_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.xfre.2024.05.007","volume":"5","author":"R Mandelbaum","year":"2024","unstructured":"Mandelbaum R, Stanczyk FZ (2024) Progesterone in frozen embryo transfer cycles: assays, circulating concentrations, metabolites, and molecular action. F S Rep 5(3):237\u2013247. https:\/\/doi.org\/10.1016\/j.xfre.2024.05.007","journal-title":"F S Rep"},{"issue":"5","key":"5525_CR8","doi-asserted-by":"publisher","first-page":"QC01","DOI":"10.7860\/JCDR\/2023\/56291.17889","volume":"17","author":"S Mehta","year":"2023","unstructured":"Mehta S, Chaturvedi A (2023) Comparison of the pharmacokinetics, bioequivalence and safety of aqueous progesterone formulation administered as either intramuscular or subcutaneous injection versus oil-based progesterone formulation administered as intramuscular injection: a randomised study. J Clin Diagn Res 17(5):QC01\u2013QC06. https:\/\/doi.org\/10.7860\/JCDR\/2023\/56291.17889","journal-title":"J Clin Diagn Res"},{"issue":"4","key":"5525_CR9","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1208\/s12248-009-9142-z","volume":"11","author":"KK Midha","year":"2009","unstructured":"Midha KK, McKay G (2009) Bioequivalence; its history, practice, and future. AAPS J 11(4):664\u2013670. https:\/\/doi.org\/10.1208\/s12248-009-9142-z","journal-title":"AAPS J"},{"issue":"6","key":"5525_CR10","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/BF01068419","volume":"15","author":"DJ Schuirmann","year":"1987","unstructured":"Schuirmann DJ (1987) A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15(6):657\u2013680. https:\/\/doi.org\/10.1007\/BF01068419","journal-title":"J Pharmacokinet Biopharm"},{"issue":"4","key":"5525_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.clinthera.2024.12.015","volume":"47","author":"R Song","year":"2025","unstructured":"Song R, Wu X, Xin L, Sun C, Gui Y, Qian H, Yu C, Chen Q, Luo T, Ding Y, Gao W, Zhu X, Jia J (2025) Bioequivalence of water-soluble progesterone injection (GenSci070) in healthy Chinese postmenopausal women volunteers. Clin Ther 47(4):271\u2013276. https:\/\/doi.org\/10.1016\/j.clinthera.2024.12.015","journal-title":"Clin Ther"},{"issue":"2","key":"5525_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.70025","volume":"15","author":"N Vyas","year":"2026","unstructured":"Vyas N, Chakra A, Sarode P, Dharmadhikari S, Puppalwar G, Khandhedia C, Mane A, Goyani A, Khopade AJ (2026) A comparative pharmacokinetic evaluation of two aqueous progesterone 25 mg injections in healthy postmenopausal women under fasting conditions: an open-label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study. Clin Pharmacol Drug Dev 15(2):e70025. https:\/\/doi.org\/10.1002\/cpdd.70025","journal-title":"Clin Pharmacol Drug Dev"},{"key":"5525_CR13","unstructured":"U.S. Food and Drug Administration (2007)\u00a0Progesterone injection prescribing information\/label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/017362s104lbl.pdf.\u00a0Accessed 26 Feb 2026"},{"key":"5525_CR14","unstructured":"U.S. Food and Drug Administration (2001) Guidance for industry: statistical approaches to establishing bioequivalence. https:\/\/www.fda.gov\/media\/70958\/download.\u00a0Accessed 26 Feb 2026"},{"key":"5525_CR15","unstructured":"U.S. Food and Drug Administration (2018) Bioanalytical method validation: guidance for industry. https:\/\/www.fda.gov\/media\/70858\/download.\u00a0Accessed 26 Feb 2026"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05525-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05525-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05525-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:04:55Z","timestamp":1787670295000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05525-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5525"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05525-0","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"23 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This single-center study (Study Code: Pro25085; Protocol Code: Zi-Pro\/Mar-0925\u201358) was conducted in accordance with the Declaration of Helsinki, the International Council for Harmonisation Good Clinical Practice guidelines, and applicable local regulations. The protocol and informed consent documents were reviewed and approved by the Independent Ethics Committee of Zi Diligence Biocenter before initiation of study procedures (protocol version 1.0 approved on 30 September 2025; protocol version 2.0 approved on 7 November 2025).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all subjects involved in the study before any study-specific procedures were performed.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}